Skip to main content
Guerbet logo

Guerbet — Investor Relations & Filings

Ticker · GBT ISIN · FR0000032526 LEI · 969500WV1U1WQ059L135 PA Manufacturing
Open in API
Filings indexed 623 across all filing types
Latest filing 2013-11-12 Declaration of Voting R…
Country FR France
Listing PA GBT

About Guerbet

https://www.guerbet.com

Guerbet is a global specialist in medical imaging, offering a comprehensive range of solutions and services for diagnostic and interventional procedures. The company develops and manufactures contrast media, medical devices such as injectors, and related software for X-ray, Magnetic Resonance Imaging (MRI), and Interventional Imaging. With a history of innovation dating back to 1926, Guerbet focuses on providing healthcare professionals with tools to enhance diagnostic accuracy and improve patient care. Its portfolio is designed to support a wide array of clinical applications, from initial diagnosis to treatment monitoring.

Recent filings

Filing Released Lang Actions
Guerbet - Nombre d'actions et de droits de vote composant le capital au 31 octobre 2013
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a press release dated November 12, 2013, titled 'DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE' (Declaration relative to the number of voting rights and shares comprising the capital of the company). It explicitly references compliance with French commercial code (L. 233-8 II) and AMF regulations (article 222-12-5) for publishing the total number of voting rights and shares monthly if they have changed. The content is a table detailing the total shares, treasury shares, and total voting rights as of October 31, 2013. This specific reporting requirement, focusing on the total count of voting rights and shares, aligns directly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or related statutory declarations about voting power.
2013-11-12 French
GUERBET - Dotarem® (gadotérate de méglumine), solution injectable, est désormais référencé par Novation, la plus importante centrale d’achats aux USA
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a business development: Guerbet LLC (USA) securing a contract for its product Dotarem® with Novation, a major US purchasing organization. This type of announcement, detailing a commercial agreement, partnership, or significant business event, is typically classified as a general regulatory announcement or press release that doesn't fit into the highly specific financial reporting categories (like 10-K, ER, or DIV). Since it is a formal announcement but not a specific financial report, the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general regulatory disclosure/announcement.
2013-11-12 French
GUERBET - Dotarem® (gadoterate meglumine) Injection Now Offered Via Novation, USA’s Leading Group Purchasing Organization
Regulatory Filings Classification · 95% confidence The document is explicitly titled '# **P R ES S RE L E AS E**' and announces a business development: Guerbet LLC (USA) securing a new agreement for their product Dotarem® via Novation, a GPO. This is a standard corporate announcement regarding commercial activity, not a formal regulatory filing like a 10-K, an earnings report (ER), or a detailed management discussion (MDA). Since it is a press release announcing a commercial/business event, it does not fit neatly into the specific financial report categories. Therefore, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that are not otherwise classified.
2013-11-12 English
Guerbet - Chiffre d'affaires du 3ème trimestre 2013
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and specifically details the "Chiffre d'affaires du 3ème trimestre 2013" (Third Quarter 2013 Revenue). It presents key financial figures (revenue by quarter and geography) for a specific reporting period (Q3 2013) but is presented as a brief announcement rather than a comprehensive, detailed report like a 10-K or a full Interim Report (IR). This format, focusing on the initial release of period results, aligns best with the definition of an Earnings Release (ER). The document length (2769 chars) also supports it being a release rather than a full report. Q3 2013
2013-10-23 French
Guerbet - 2013 third-quarter revenue
Earnings Release Classification · 98% confidence The document is titled '2013 third-quarter revenue' and presents consolidated group revenue figures broken down by quarter and region for the first nine months of 2013 compared to 2012. It includes key financial highlights and commentary on business segments (MRI, X-Ray). This structure is characteristic of an initial announcement of periodic financial results, focusing on key figures rather than the comprehensive detail found in a full Interim Report (IR) or Annual Report (10-K). Therefore, it fits the definition of an Earnings Release (ER). The document length (2404 chars) is short, but it contains the core results, not just an announcement that results are available. 9M 2013
2013-10-23 English
Guerbet - La FDA accorde le statut de médicament orphelin à Lipiodol®
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that the FDA granted Orphan Drug Status to Lipiodol® for the treatment of hepatocellular carcinoma. This is a specific, time-sensitive announcement regarding regulatory action and product development, not a comprehensive annual report (10-K), interim report (IR), or a general earnings release (ER). It is a specific regulatory/product update. Since it is a press release announcing a specific regulatory event (Orphan Drug Status grant by the FDA), it fits best under the general category for regulatory announcements that aren't explicitly covered by other codes like DIRS, DIV, or CAP. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general regulatory announcement press release that doesn't fit the more specific categories like M&A (TAR) or Capital Changes (CAP). However, since it is a specific announcement about a regulatory decision impacting a drug, and it is not a full financial report, it is best classified as a general regulatory filing/announcement.
2013-10-21 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.